|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.22 USD | -3.21% |
|
-4.09% | -1.17% |
| 08/05 | Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M | MT |
| 08/05 | Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Sept 12 (Reuters) - Cell and gene therapy company 2seventy bio said on Tuesday that CEO Nick Leschly will step down.
The company also said it plans to lay off about 40% of its current workforce. (Reporting by Pratik Jain in Bengaluru; Editing by Shounak Dasgupta)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.17% | 22Cr | |
| +43.36% | 5.81TCr | |
| -5.31% | 4.05TCr | |
| +37.52% | 3.9TCr | |
| +14.75% | 2.67TCr | |
| -12.56% | 2.66TCr | |
| -22.45% | 1.9TCr | |
| +0.04% | 1.22TCr | |
| +25.12% | 1.2TCr | |
| +26.04% | 1.19TCr |
2SEVENTY BIO, INC. 
